Simcyp® Simulator is the industry’s leading PBPK platform for assisting in dose selection and informing labeling.
Identify drug toxicity earlier
A major challenge in developing efficacious and safe drugs is the ability to understand and effectively predict adverse effects of xenobiotic substances on extremely complex biological systems early in the drug discovery process. Many adverse drug reactions (ADRs) cannot reliably be predicted by current pre-clinical animal testing and existing modeling methodologies. Quantitative systems toxicology and safety (QSTS) can help to predict ADRs earlier and provide additional benefits.
Simcyp™ QSTS is the integration of classical toxicology with quantitative analysis of large networks of molecular and functional changes occurring across multiple levels of biological organization.
The availability of vast amounts of high quality ‘omics data (e.g., genomics, proteomics, transcriptomics, metabolomics) and relationship databases, combined with advanced computational and analytical tools, has spurred a move towards QSTS modeling to better understand the mechanistic basis of ADRs and achieve a more predictive and accurate approach to risk assessment.
Engage our expert QSTS scientific consultants to identify drug toxicity earlier and decrease time to bring your drugs to market.
QSP examines relationships between a drug, biological system, and disease process.
The Simcyp Consortium is a research collaboration for PBPK and mechanistic modeling.
Predict off-target adverse events earlier and faster with Secondary Intelligence software
Approximately 25% of attrition in drug programs occurs due to safety issues, of which some arise from secondary pharmacology. De-risk your program with evidence-based secondary pharmacology insights with our NEW Secondary Intelligence software. This one and only software of its kind allows researchers to automate, streamline and standardize secondary pharmacology analysis and increase confidence in critical go/no go decisions. With our consulting services, our team of scientists can help to advance your program, powered by our Secondary Intelligence technology.
- Rates each compound with a ‘low,’ ‘intermediate,’ or ‘high’ likelihood of causing adverse events at the off-target receptor in clinical use
- Prioritises “receptor interactions of concern” and ranks project compounds against each other to inform quantitatively-based go/no-go decisions
- Assembles curated and up-to-date safety information about each receptor and a compound’s secondary pharmacology readouts and analysis in one place
Key benefits of QSTS
- Decrease cost and time to bring new drugs to market by identifying drug toxicity earlier
- Better forecast the impact of xenobiotic substances on biological systems
- Quantify off-target interactions and reduce ADR risk
- Strengthen drug safety assessments and reduce animal testing
- Gain better understanding of drug-induced toxicity
- Identify new biomarkers
Accelerating QSTS progress
Certara’s Simcyp division has been awarded three grants to accelerate the move toward systems toxicology using mechanism-based chemical safety testing strategies.
These grants were awarded by the following initiatives:
• EU ToxRisk/Tox 21—a collaboration to reduce use of animals and achieve efficient chemical safety assessments
• Trans QST—an organization that focuses on Translational Safety and integration of pre-clinical and clinical data to analyze the predictive robustness of animal studies
• eTranSafe—an EU consortium to assemble and curate large datasets and European Federation of Pharmaceutical Industries and Association’s legacy data
Will leads the QSTS team to apply computational approaches to assess the safety of pharmaceuticals and other chemicals. He is an experienced safety pharmacologist, having worked at Syntex, Quintiles and AstraZeneca. He is a former President of the Safety Pharmacology Society.
Mark has over 30 years of experience in drug discovery and development gained at Celltech, AstraZeneca, Pfizer and Covance, and provides expert advice on safety pharmacology and toxicology to the QSTS team.
Will leads the QSTS team to apply computational approaches to assess the safety of pharmaceuticals and other chemicals. He is an experienced safety pharmacologist, having worked at Syntex, Quintiles and AstraZeneca. He is a former President of the Safety Pharmacology Society.
Mark has over 30 years of experience in drug discovery and development gained at Celltech, AstraZeneca, Pfizer and Covance, and provides expert advice on safety pharmacology and toxicology to the QSTS team.